Oxymetholone


Concise Prescribing Info
Indications/Uses
Anaemia.
Dosage/Direction for Use
Adult : PO 1-5 mg/kg/day for 3-6 mth.
Dosage Details
Oral
Anaemia
Adult: 1-5 mg/kg daily for 3-6 mth.
Child: Same as adult dose.
Hepatic Impairment
Severe: Contraindicated.
Contraindications
Prostate and breast cancer, nephrosis. Severe hepatic impairment. Pregnancy and lactation.
Special Precautions
Patient w/ oedematous conditions (e.g. migraine, seizure disorder, CV disease), DM. Renal and mild to moderate hepatic impairment. Childn.
Adverse Reactions
Significant: Benign hepatic tumours, blood lipid changes, mild virilisation, benign prostatic hypertrophy (elderly males), clotting factor alterations.
Nervous: Excitation, insomnia, deepening of voice (female).
CV: Coronary artery diseas, peripheral oedema.
GI: Nausea, vomiting, diarrhoea.
Hepatic: Reversible changes in hepatic function tests (e.g. increased serum bilirubin, alkaline phosphatase and glutamic-oxaloacetic transaminase, increased Bromsulphalein retention).
Genitourinary: Increased creatine and creatinine excretion, erectile dysfunction, testicular atrophy and oligospermia, impotence, chronic priapism, testicular disease, epididymitis, bladder irritability, decreased seminal volume, clitoromegaly, menstrual disease, amenorrhea (female).
Endocrine: Increased or decreased libido, decreased glucose tolerance, gynecomastia, hirsutism (female).
Haematologic: Iron-deficiency anaemia, haemorrhage, leukemia, prolonged prothrombin time (PT).
Musculoskeletal: Muscle cramps, increased creatinine phosphokinase, premature closure of epiphyses (childn).
Dermatologic: Acne, androgenic alopecia, hyperpigmentation.
Others: Chills, oedema, serum electrolytes retention.
Potentially Fatal: Peliosis hepatitis, malignant hepatic tumours, cholestatic jaundice w/ hepatic necrosis.
MonitoringParameters
Periodically monitor LFT, lipid profile, serum iron and iron binding capacity, Hb and haematocrit levels. Monitor radiologic examination of bones every 6 mth (prepubertal childn); urine and serum Ca, signs of virilisation in female patient treated for breast cancer. 
Drug Interactions
Increased fluid-retention effect w/ adrenal steroids or ACTH. May enhance anticoagulant effect (e.g. increased INR/PT) of warfarin. May increase hepatotoxic effect of cyclosporine. May enhance hypoglycaemic effect of blood glucose lowering agents. May increase risk of cholestasis of ajmaline. 
Lab Interference
Decreased thyroxine-binding globulin, T4. Increased resin uptake of T3 and T4.
Action
Description: Oxymetholone is an anabolic steroid. It is used to treat anaemia (due to bone marrow failure and decreased RBC production) by increasing erythropoietin and stimulating erythropoiesis. It is also a synthetic derivative of testosterone and can suppress the gonadotropic functions of the pituitary.
Chemical Structure

Chemical Structure Image
Oxymetholone

Source: National Center for Biotechnology Information. PubChem Database. Oxymetholone, CID=5281034, https://pubchem.ncbi.nlm.nih.gov/compound/Oxymetholone (accessed on Jan. 22, 2020)

Storage
Store between 20-25°C.
MIMS Class
ATC Classification
A14AA05 - oxymetholone ; Belongs to the class of androstan derivative anabolic steroids used as systemic anabolic agents.
References
Anadrol-50 Oxymetholone Tablet (Alaven Pharmaceutical). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 18/09/2017.

Anon. Oxymetholone. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 18/09/2017.

Buckingham R (ed). Oxymetholone. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 18/09/2017.

Disclaimer: This information is independently developed by MIMS based on Oxymetholone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in